HD-CAB is an instrument to facilitate patient-oriented research and clinical trials as well as fair processes to make treatment accessible for all patients. HD-CAB has a global perspective with members from 6 out of the 7 continents and the main aims are 2:
- Coordinate with pharmaceutical companies and our global advisory team to ensure research progression is effective and meets the needs of the patients and families
- Advocate with governing bodies globally to make drugs accessible to the HD community